Antidepressants Market to Register 2.9% CAGR till 2027; Increasing Prevalence of Social Anxiety Disorders to Positively Influence the Market

The global antidepressants market size is projected to reach USD 18.29 billion by 2027, owing to the rising sales of prescription drugs for managing depression at retail pharmacies, states Fortune Business Insights™ in its report, titled “Antidepressants Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Selective Serotonin Reuptake Inhibitors, Serotonin & Norepinephrine Reuptake Inhibitors, Atypical Antidepressants, Tricyclic Antidepressants, & Atypical Antipsychotics), Monoamine Oxidase Inhibitors),  By Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, & Online Pharmacy), and Regional Forecast, 2020-2027        ”. The report further states that the value of the market was USD 11.67 billion in 2019 and the market is expected to showcase a CAGR of 2.9% from 2020 to 2027.

The COVID-19 pandemic has proven to be beneficial for market’s growth as the uncertainty and upheavals (economic, political, social, and psychological) triggered by this crisis has sharply raised the prevalence of depression and related disorders. Pharmaceutical companies have been reporting surging sales of their mental health medications amid this pandemic and as a result of the positive demand shock, the market displayed a stellar CAGR of 28.0% in 2020 and hit a value of USD 14.93 billion.

Biogen and Sage to Co-develop Therapies for Depression & Movement Disorders

In November 2020, Biogen Inc. and Sage Therapeutics announced that the two companies will be collaboration to jointly develop and commercialize Sage’s breakthrough therapies for major depressive disorder (MDD), postpartum depression (PPD), and other psychiatric conditions, as well as its treatments for essential tremor and other neurological disorders. Biogen will receive an exclusive license to develop and commercially distribute zuranolone (for MDD and PPD) and SAGE-324 (for movement disorders) outside of the US. The partnership will unify Sage’s expertise in psychiatry medications and Biogen’s capabilities in neuroscience and the combined strengths will enable both companies to rapidly expand their research and innovation capacities.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/antidepressants-market-105017

Known Side Effects of Antidepressants to Limit Growth

With the awareness about debilitating mental health issues, such as anxiety and depression, steadily spreading, the uptake of anti-depressants and other such drugs has increased worldwide. While these medications are playing an instrumental role in maintaining the mental stability of the affected persons, their well-known physiological side effects have limited their adoption among patients. For example, according to Harvard Medical School, selective serotonin reuptake inhibitors (SSRIs) can weaken the blood clotting capacity of the body as these depression medications can reduce the concentration of serotonin in platelets. Further, SSRIs can considerably diminish sexual interest, satisfaction, and performance, Harvard Medical highlights. On the other hand, according to the National Health Service of the UK, serotonin-noradrenaline reuptake inhibitors (SNRIs) can lead to insomnia, dizziness, indigestion, and loss of appetite. Various classes of antidepressants can, therefore, result in different adverse effects on the body, which may make patients hesitant before consuming them.

Leading Competitors to Adopt Novel Position Strengthening Strategies

The competitive landscape of this market is getting charged up as key players adopt innovative strategies to strengthen their position in the market. For example, many companies are partnering with health service providers to amplify the reach of antidepressants among untouched customers. Moreover, these participants are seeking opportunities to establish in the untapped, emerging markets of Asia and Africa to further bolster their international presence.

Industry Development:

• July 2020: Canabo Medical, a subsidiary of Aleafia Health, secured approval from Janssen Pharmaceuticals to be an administrator and prescriber of SPRAVATO, Janssen’s antidepressant nasal spray.

List of Key Player Profiled in this Market Report:

• Bristol-Myers Squibb (New York, U.S)


• Merck & Co. Inc. (New Jersey, U.S)


• Janssen Pharmaceuticals (Beerse, Belgium)


• GlaxoSmithKline plc (Brentford, U.K)


• Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)


• AstraZeneca (Cambridge, U.K)


• Pfizer Inc. (New York, U.S)


• Eli Lilly and Company (Indiana, U.S)


• H. Lundbeck A/S (Denmark, Europe)

Further Report Findings:

• The selective serotonin reuptake inhibitors segment led the market in 2019 with a share of 27.4% and is likely to retain its commanding hold on the market as SSRIs are known to be highly effective in lowering an individual’s depressive mindset.


• North America is expected to dictate the market share during the forecast period due to the high incidence of different types of mental health issues in the US. The region’s market size was USD 6.00 billion in 2019.

Table of Segmentation